Bacterial Vaginosis Market is segmented By Treatment (Antibiotics (Metronidazole, Clindamycin, Tinidazole), Antifungal AgentsProbiotics), By Route of ....
Market Size in USD Bn
CAGR8.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.7% |
Market Concentration | Medium |
Major Players | Symbiomix Therapeutics (Lupin Pharmaceuticals), Bayer AG, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries and Among Others |
The bacterial vaginosis market is estimated to be valued at USD 3.48 billion in 2024 and is expected to reach USD 6.26 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2031.
The market has been witnessing positive trends over the past few years. Factors such as rising prevalence of bacterial vaginosis infections and growth in female population have been driving the adoption of bacterial vaginosis treatment and diagnostics.